A Study of [14C]-LY4065967 in Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 23, 2025

Primary Completion Date

August 16, 2025

Study Completion Date

August 16, 2025

Conditions

Healthy

Interventions

DRUG

LY4065967

Oral dose

RADIATION

[14C]-LY4065967 Oral

Oral dose

RADIATION

[14C]-LY4065967 IV

IV dose

Trial Locations (1)

Fortrea Clinical Research Unit, Madison

All Listed Sponsors

lead

Eli Lilly and Company

INDUSTRY

NCT07039045 - A Study of [14C]-LY4065967 in Healthy Participants | Biotech Hunter | Biotech Hunter